期刊
SEMINARS IN OPHTHALMOLOGY
卷 26, 期 3, 页码 216-224出版社
TAYLOR & FRANCIS INC
DOI: 10.3109/08820538.2011.577498
关键词
cell replacement; disease models; photoreceptors; retinal pigment epithelium
资金
- National Institutes of Health [R01EY14428, RO1EY18660]
- Ronald McDonald House Charities
- Macular Vision Research Foundation
- West China Hospital of Sichuan University
There is currently no FDA-approved therapy for treating patients with geographic atrophy (GA), a late stage of age-related macular degeneration (AMD). Cell transplantation has the potential to restore vision in these patients. This review discusses how recent advancement in induced pluripotent stem (iPS) cells provides a promising therapy for GA treatment. Recent advances in stem cell biology have demonstrated that it is possible to derive iPS cells from human somatic cells by introducing reprogramming factors. Human retinal pigment epithelium (RPE) cells and photoreceptors can be derived from iPS cells by defined factors. Studies show that transplanting these cells can stabilize or recover vision in animal models. However, cell derivation protocols and transplantation procedures still need to be optimized. Much validation has to be done before clinical-grade, patient-derived iPS can be applied for human therapy. For now, RPE cells and photoreceptors derived from patient-specific iPS cells can serve as a valuable tool in elucidating the mechanism of pathogenesis and drug discovery for GA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据